These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42 related articles for article (PubMed ID: 6316763)
21. Striatal gray matter loss in Huntington's disease is leftward biased. Mühlau M; Gaser C; Wohlschläger AM; Weindl A; Städtler M; Valet M; Zimmer C; Kassubek J; Peinemann A Mov Disord; 2007 Jun; 22(8):1169-73. PubMed ID: 17394246 [TBL] [Abstract][Full Text] [Related]
22. Molecular diagnosis of Huntington's disease in Mexican patients by polymerase chain reaction. Cisneros Vega B; Alonso Vilatela ME; Yescas Gomez P; Silva Arreola G; Montañez Ojeda C Arch Med Res; 1996; 27(1):87-92. PubMed ID: 8867374 [TBL] [Abstract][Full Text] [Related]
23. Parameter-based assessment of spatial and non-spatial attentional deficits in Huntington's disease. Finke K; Bublak P; Dose M; Müller HJ; Schneider WX Brain; 2006 May; 129(Pt 5):1137-51. PubMed ID: 16504973 [TBL] [Abstract][Full Text] [Related]
24. Neuroacanthocytosis misdiagnosed as Huntington's disease: a case report. Meenakshi-Sundaram S; Arun Kumar MJ; Sridhar R; Rani U; Sundar B J Neurol Sci; 2004 Apr; 219(1-2):163-6. PubMed ID: 15050453 [TBL] [Abstract][Full Text] [Related]
25. The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease. Alexi T; Hughes PE; van Roon-Mom WM; Faull RL; Williams CE; Clark RG; Gluckman PD Exp Neurol; 1999 Sep; 159(1):84-97. PubMed ID: 10486177 [TBL] [Abstract][Full Text] [Related]
27. Post-mortem findings do not suggest a brain glutamine deficiency in Huntington's disease. Perry TL Lancet; 1981 Jun; 1(8232):1261-2. PubMed ID: 6112587 [No Abstract] [Full Text] [Related]
28. Loss of glutamine synthetase activity in the brain in Huntington's disease. Carter CJ Lancet; 1981 Apr; 1(8223):782-3. PubMed ID: 6110984 [No Abstract] [Full Text] [Related]
29. Regional and subcellular distribution of superoxide dismutase in brain. Loomis TC; Yee G; Stahl WL Experientia; 1976 Nov; 32(11):1374-6. PubMed ID: 136361 [TBL] [Abstract][Full Text] [Related]
30. Neurobiology and pharmacology of Huntington's disease. Enna SJ Life Sci; 1977 Jan; 20(2):205-11. PubMed ID: 190505 [No Abstract] [Full Text] [Related]
31. Enzymes associated with the metabolism of catecholamines, acetylcholine and gaba in human controls and patients with Parkinson's disease and Huntington's chorea. McGeer PL; McGeer EG J Neurochem; 1976 Jan; 26(1):65-76. PubMed ID: 3629 [No Abstract] [Full Text] [Related]
32. Recent advances in the neurochemistry of Huntington's disease. Wastek GJ; Stern LZ; Yamamura HI Ariz Med; 1977 Aug; 34(8):547-8. PubMed ID: 143259 [No Abstract] [Full Text] [Related]
33. Normal glutamic acid decarboxylase activity in kidney tissue from patients with Huntington's Disease. Bird TD J Neurochem; 1976 Dec; 27(6):1555-7. PubMed ID: 137300 [No Abstract] [Full Text] [Related]
34. [Importance of the number of trinucleotide repeat expansions in the clinical manifestations of Huntington's chorea]. Vojvodić N; Culjković B; Romac S; Stojković O; Sternić N; Sokić D; Kostić VS Srp Arh Celok Lek; 1998; 126(3-4):77-82. PubMed ID: 9863360 [TBL] [Abstract][Full Text] [Related]
35. Low arterial blood pressure in Huntington's disease: low body weight- or brain chemical changes-related? Preliminary report. Campanella G; Di Maio L; Postiglione A; Annuzzi G Acta Neurol (Napoli); 1983 Aug; 5(4):256-9. PubMed ID: 6316763 [No Abstract] [Full Text] [Related]